Skip to main content
ClinicalTrials.govcontrolled

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple

ClinicalTrials.gov study NCT02484404. IPD Sharing: YES. Countries: 1. Publications: 3.

ShareScore

32/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
12
Access
0
Reuse readiness
0
Engagement
8

Topics